Sanofi CEO Paul Hudson believes 2023 will be one of “the most important years in the company’s history.” The French pharmaceutical giant is riding on the success of Dupixent with positive data for COPD patients while bidding farewell to the last major patent expiry with several years left.
in an exclusive interview with endpoint newsHudson spoke about the company’s pipeline, whether it was involved in Ciegen’s bid, how US antitrust laws might affect future deals, Congressional insulin hearings, GLP-1 drugs, and more. Told. (For the full text of the Dupixent data, see click here. )
Continue reading endpoints with a free subscription
Unlock this story now and join over 169,400 biopharmaceutical professionals who read endpoints every day. And it’s free.